Phase III Randomized, Double-Blind Study of CAI and Placebo in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2017
At a glance
- Drugs L 651582 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Jun 2017 Results comparing nocebo effects in older patients (n=446) enrolled in cancer therapeutic trials (NCCTG97-24-51 and ACOSOG Z9001), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 21 Dec 2010 Actual end date changed from Mar 2008 to Nov 2010 as reported by ClinicalTrials.gov.